| Literature DB >> 35910523 |
Jaahnavi Lanka1, Santhosh Kumar1, Mohana Kumar B2, Shama Rao2, Shivaprasad Gadag3, Usha Y Nayak3.
Abstract
Hyaluronic acid (HA) is a naturally occurring biopolymer, with a remarkable wound healing property. Zinc-oxide non-eugenol is a material widely used for periodontal dressing in dentistry. However, it has been reported that zinc oxide non-eugenol is toxic to osteoblasts and fibroblasts. Hence, the present study aimed to evaluate the drug release and cytotoxicity of HA and zinc-oxide gels. Hydrogels of HA and zinc oxide were formulated with carbopol as a carrier. In vitro drug release was performed by UV spectrophotometry, dialysis, and vial bag methods. Cytotoxicity assessment of HA and zinc-oxide gels was performed in human periodontal ligament fibroblasts (HPdLF) and human gingival fibroblasts (hGFs). An inverted phase-contrast microscope was used to assess the morphological changes. At 24 and 48 hr, HPdLF cells showed the highest viability in 0.1% low molecular weight-HA (LMW-HA) with a median value of 131.9, and hGFs showed the highest viability in 5% LMW-HA with a median of 129.56. The highest viability of HPdLF cells was observed in 5% high molecular weight-HA (HMW-HA), with a median value of 127.11. hGFs showed the highest viability in 1% HMW-HA with a median value of 97.99. Within the limitations of the present study, we concluded that LMW-HA is more efficient than HMW-HA. Both HPdLF and hGF cells showed complete cell morbidity with zinc-oxide hydrogels. Therefore, zinc oxide-based gels in concentrations as low as 9% could be toxic intraorally to soft tissues that harbor gingival and periodontal ligament fibroblasts.Entities:
Keywords: Dressing; Zinc-oxide; hyaluronic acid; hydrogel; molecular weight; periodontal surgery; wound healing
Year: 2022 PMID: 35910523 PMCID: PMC9327778 DOI: 10.1080/15685551.2022.2099647
Source DB: PubMed Journal: Des Monomers Polym ISSN: 1385-772X Impact factor: 3.718
Figure 1.Study design.
Study groups.
| Group A – Zinc Oxide Gels | Group B – Hyaluronic acid Gels |
|---|---|
| I. 87% w/v (POSITIVE CONTROL) | |
0.1% 1% 5% 10% | |
0.1% 1% 5% 10% |
(LMW-HA: Low molecular weight hyaluronic acid; HMW-HA: High molecular weight hyaluronic acid.)
Figure 2.Drug release pattern of different concentrations of LMW-HA by UV spectrophotometry. (LMW-HA: Low molecular weight hyaluronic acid; UV: Ultraviolet).
Comparison of cell viability between the LMW-HA and HMW-HA groups.
| Time intervals | Concentrations | Chi-Square value | p value |
|---|---|---|---|
| 24 hr | 0.10% | 1.985 | 0.575 |
| 1% | 1.963 | 0.580 | |
| 5% | 1.875 | 0.599 | |
| 10% | 13.125 | 0.004* | |
| 48 hr | 0.10% | 7.743 | 0.052 |
| 1% | 1.875 | 0.599 | |
| 5% | 6.684 | 0.083 | |
| 10% | 10.891 | 0.012* | |
| 72 hr | 0.10% | 6.296 | 0.098 |
| 1% | 2.713 | 0.438 | |
| 5% | 5.382 | 0.146 | |
| 10% | 11.272 | 0.010* |
*Significant
(LMW-HA: Low molecular weight Hyaluronic acid; HMW-HA: High molecular weight Hyaluronic acid; HPdLF: Human periodontal ligament fibroblasts; hGFs: Human gingival fibroblasts)
Comparison of viability values at different time intervals among different concentrations within the groups.
| 24 hr | 48 hr | 72 hr | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Conc (%) | Median (Min – Max) | IQR | p value | Median (Min – Max | IQR | p value | Median (Min – Max | IQR | P value | |
| LMW-HA-HPDL | 0.10 | 131.93(89.2 − 239.2) | 130.5 | 0.8 | 103.41 (71.22–198.68) | 99.44 | 0.4 | 134.68 (130.67 | 9.68 | 0.008* |
| 1 | 125.47 (68.2–141.9) | 57.65 | 95.04 (73.08–106.18) | 25.96 | 67.83 (40.54–86.17) | 38.01 | ||||
| 5 | 116.74 (78.36–168.49) | 78.86 | 112.74(91.22–119.39) | 23.45 | 95.65 (78.75–107.21) | 25.54 | ||||
| 10 | 107.65 (87.45–117.24) | 24.72 | 28.16 | 93.5 (80.82–95.19) | 11.05 | |||||
| LMW-HA-HGF | 0.10 | 97.76 (56.95–162.17) | 93.48 | 0.6 | 70.69 (51.3–81.95) | 23.61 | 0.9 | 95.95 (57.86–115.95) | 43.65 | 0.54 |
| 1 | 106.08 (60.89–150.93) | 72.85 | 62.32 (57.77–104.8) | 36.83 | 91.1 (57.61–112.93) | 42.73 | ||||
| 5 | 129.56 (52.59–158.23) | 91.73 | 73.68 (52.21–115.14) | 49.92 | 107.38 (72.18–134.43) | 46.82 | ||||
| 10 | 82.34 (55.0–99.2) | 36.59 | 70.92 (49.83–85.09) | 26.65 | 107.91 (87.81–130.76) | 35.26 | ||||
| HMW-HA-HPDL | 0.10 | 99.15 (81.06–111.33) | 24.82 | 0.02* | 99.15 (81.06–111.33) | 24.82 | 0.02* | 119.22 (104.51–141.96) | 30.14 | 0.01* |
| 1 | 109.39 (93.84–160.59) | 51.49 | 109.39 (93.84–160.59) | 51.49 | 77.22 (62.32–127.31) | 50.77 | ||||
| 5 | 127.11 (63.73–213.9) | 114.38 | 127.11 (63.73–213.9) | 114.38 | 88.61 (84.05–91.56) | 6.05 | ||||
| 10 | 50.52 (40.32–59.91) | 15.41 | 50.52 (40.32–59.91) | 15.41 | 59.87 (50.68–61.94) | 8.82 | ||||
| HMW-HA-HGF | 0.10 | 87.62 (46.8–132.9) | 70.89 | 0.03* | 87.62 (46.8–132.9) | 70.89 | 0.03* | 105.76 (75–136.73) | 59.08 | 0.25 |
| 1 | 97.99 (89.39–104.17) | 11.41 | 97.99 (89.39–104.17) | 11.41 | 80.71 (71.69–87.79) | 13.3 | ||||
| 5 | 91.68 (57.78–106.6) | 39.65 | 91.68 (57.78–106.6) | 39.65 | 78.58 (67.51–84.66) | 15.64 | ||||
| 10 | 22.36 (17.9–33.31) | 11.83 | 22.36 (17.92–33.31) | 11.83 | 65.21 (57.23–91.78) | 26.87 | ||||
P value calculated using Kruskal–Wallis test; *Significant
(LMW-HA: Low molecular weight hyaluronic acid; HMW-HA: High molecular weight hyaluronic acid; HPdLF: Human periodontal ligament fibroblasts; hGFs: Human gingival fibroblasts)
Comparison of the viability values within the groups at subsequent time intervals.
| Variables | 0.10% | 1.00% | 5% | 10% | |
|---|---|---|---|---|---|
| LMW-HA | PDL | 0.77 | 0.17 | 0.17 | 0.47 |
| HGF | 0.36 | 0.36 | 0.36 | 0.039* | |
| HMW-HA | PDL | 0.039* | 0.17 | 0.17 | 0.039* |
| HGF | 0.47 | 0.36 | 0.36 | 0.018* | |
P value calculated using Friedman test; *Significant (LMW-HA: Low molecular weight hyaluronic acid; HMW-HA: High molecular weight hyaluronic acid; HPdLF: Human periodontal ligament fibroblasts; hGFs: Human gingival fibroblasts)
Figure 3.96-Well microplates used for cytotoxicity with all the experimental groups.